Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.

•The adjuvanted recombinant zoster vaccine (RZV) is licensed for herpes zoster prevention in ≥50-year-olds.•Post-licensure spontaneous safety reports received up to February 10, 2019 were reviewed.•Of 15,638 reports, most were non-serious, from US, and associated with known vaccine reactogenicity.•No unexpected reporting patterns were detected overall.•The RZV safety profile was consistent with that observed in clinical trials.